Inactive Instrument

Company Acacia Pharma Group plc

Equities

ACPH

GB00BYWF9Y76

Business Summary

Acacia Pharma Group plc specializes in the research and development of supportive care medicines. The products are intended to support the side effects of anti-cancer treatments (including nausea and vomiting drugs).

At the end of 2021, the group had a portfolio of 3 products, including 1 in phase II of clinical development (APD403; treatment of chemically induced nausea and vomiting) and 2 in pre-launch phase: BARHEMSYS (treatment of nausea and postoperative vomiting) and BYFAVO (benzodiazepine sedative for use in invasive medical procedures in adults, such as colonoscopy and bronchoscopy).

Number of employees: 76

Managers

Managers TitleAgeSince
Chief Executive Officer - 15-07-31
Chairman 54 15-02-28
Chief Tech/Sci/R&D Officer - 07-12-31
Corporate Officer/Principal - 21-05-18
Corporate Secretary - 20-02-28

Members of the board

Members of the board TitleAgeSince
Director/Board Member 65 18-02-28
Director/Board Member 69 18-02-28
Chairman 54 15-02-28
- -
Director/Board Member - -

Company contact information

Acacia Pharma Group Ltd.

The Officers' Mess Royston Road

CB22 4QH, Duxford

+44 1223 919760

http://www.acaciapharma.com
address Acacia Pharma Group plc(ACPH)

Sector

This company's sector is not yet available